A novel method for isolation of histones from serum and its implications in therapeutics and prognosis of solid tumours by unknown
METHODOLOGY Open Access
A novel method for isolation of histones
from serum and its implications in
therapeutics and prognosis of solid
tumours
Divya Reddy1,2, Bharat Khade1, Riddhi Pandya1 and Sanjay Gupta1,2*
Abstract
Background: Dysregulation in post-translational modifications of histones and their modifiers are now well-
recognized as a hallmark of cancer and can be used as biomarkers and potential therapeutic targets for disease
progression and prognosis. In most solid tumours, a biopsy is challenging, costly, painful or potentially risky for the
patient. Therefore, non-invasive methods like ‘liquid biopsy’ for analysis of histone modifications and their modifiers
if possible will be helpful in the better clinical management of cancer patients.
Methods: Here, we have developed a cost-effective and time-efficient protocol for isolation of circulating histones
from serum of solid tumor, HCC, called Dual Acid Extraction (DAE) protocol and have confirmed by mass
spectrometry. Also, we measured the activity of HDACs and HATs in serum samples.
Results: The serum purified histones were profiled for changes in histone PTMs and have shown a comparable pattern of
modifications like acetylation (H4K16Ac), methylation (H4K20Me3, H3K27Me3, H3K9Me3) and phosphorylation (γ-H2AX and
H3S10P) to paired cancer tissues. Profiling for the histone PTM changes in various other organs of normal and tumor bearing
animal suggests that the changes in the histone PTMs observed in the tumor serum is indeed due to changes in the tumor
tissue only. Further, we demonstrate that the observed hypo-acetylation of histone H4 in tissue and serum samples of tumor
bearing animals corroborated with the elevated HDAC activity in both samples compared to normal. Interestingly, human
normal and tumor serum samples also showed elevated HDAC activity with no significant changes in HAT activity.
Conclusions: Our study provides the first evidence in the context of histone PTMs and modifiers that liquid biopsy is a
valuable predictive tool for monitoring disease progression. Importantly, with the advent of drugs that target specific
enzymes involved in the epigenetic regulation of gene expression, liquid biopsy-based ‘real time’ monitoring will be
useful for subgrouping of the patients for epi-drug treatment, predicting response to therapy, early relapse and prognosis.
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Background
Histones are well conserved basic proteins which associate
to form an octameric core around which the DNA is
wrapped to form a nucleosome [1]. The N-terminal tails
of histones protrude out of the nucleosome and undergo a
variety of post-translational modifications (PTMs) like
acetylation, phosphorylation, methylation, sumoylation
and ubiquitination. The occurrence and functioning of
these PTMs are an orchestrated event of ‘writers’ (adds
modifications), ‘readers’ (recognizes modification) and
‘erasers’ (remove the modifications). Histone PTMs dy-
namically maintain the chromatin states, and thus any de-
regulation may lead to altered gene expression as
observed in diseases like cancer [2]. Indeed, the loss of
histone H4 lysine 16 acetylation (H4K16Ac) and lysine 20
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trimethylation (H4K20Me3) are considered as hall-
mark of most human cancers [3]. Similarly, global H3
and H4 hypo-acetylation have been proven to correl-
ate with tumour phenotype, prognostic factors and
patient outcome in breast and prostate cancers [4, 5].
Decades of research have discovered a battery of his-
tone PTMs that are altered in cancer and are now re-
ferred as ‘histone onco-modifications’, but none has
reached clinics primarily due to technological limita-
tions in the diagnosis of solid tumours.
Traditionally, cancer diagnosis and staging of solid tu-
mours are done with an imaging technique followed by
a surgical biopsy. But biopsy, being invasive, requires a
complex setting and well-trained clinician and is occa-
sionally difficult and risky for some advanced stage pa-
tients. Therefore, diagnosis or monitoring of solid
tumours utilizing circulating epigenetic biomarkers in
blood samples, if possible, will prove to be a very power-
ful tool and will overcome all the earlier limitations. In-
deed, research conducted over the last few years has
identified and detected epigenetic biomarkers associated
with cancer, including aberrant DNA methylation pat-
terns, miRNA profiles and histone signatures in body
fluids of the patients [6, 7].
The levels of circulating nucleosomes (cNUCs) and
histones are found to be elevated in a number of dis-
ease conditions like inflammation caused by bacterial
infections, autoimmune diseases like SLE, stress and
trauma [8]. cNUCs are released into the blood by apop-
totic cells during these processes [9]. Elevated levels of
cNUCs have been reported in lung, breast, colorectal,
renal and gastric cancer compared to patients with
inflammation and healthy individuals [10]. In case of
gastrointestinal tumours, a positive correlation between
cNUC levels, tumour stage and metastasis has been
established [11]. In case of advanced non-small cell
lung carcinoma and cervical cancer, a correlation be-
tween clinical outcome in response to chemotherapy
and cNUCs has been observed [12]. On circulating
DNA, hypo-methylation pattern has been established in
CRC patients [13]. Histone modifications like
H3K9me3 and H4K20me3 have been detected on
cNUCs [14]. In another study, the ratio of H3K9me3/
nucleosome and H4K20me3/nucleosome was found to
be less in serum of breast and colorectal cancer pa-
tients compared to healthy individuals [15]. Though
studies on histone PTMs on cNUCs have revealed
interesting aspects, but how similar is circulating epi-
genetic signature to solid tumour signatures in terms of
their histone PTMs and their modifiers has not been
established yet. This especially is important as because
any changes in the tissue epigenetic signature, if pos-
sible, can be read via the use of serum histones that can
act as a good prognosis and a diagnostic marker.
Here, we used a cost-effective method named as dual
acid extraction (DAE) method, to isolate pure histones
from serum with the aim to understand the correlation
between circulating histone PTM with that of solid
tumour (hepatocellular carcinoma, HCC) tissues in ani-
mal model. Furthermore, we for the first time measured
the histone acetylase (HAT) and histone deacetylase
(HDAC) activities in serum samples of normal and solid
tumour-bearing animals and human patient samples.
Methods
Animal handling and experiments
All the experiments were performed on male Sprague-
Dawley rats (spp. Rattus norvegicus) after approval of
the Institute Animal Ethics Committee (IAEC# 04/
2014), Advanced Centre for Treatment Research and
Education in Cancer and the Committee for the Purpose
of Control and Supervision on Animals, India standards.
The detailed protocol to induce liver carcinogenesis is as
previously described [16]. Tissue samples (liver, lung,
kidney and brain) were fixed in formalin and prepared
as paraffin-embedded blocks according to standard pro-
tocols. The H&E-stained sections were microscopically
reviewed for histopathological alterations to confirm
normal and HCC. Post-anaesthesia, the blood was slowly
collected by cardiac puncture (preferably from ventricle)
from 120 days NDEA (late stage liver cancer)-treated an-
imals after which they were sacrificed [17]. For early
stage liver cancer, blood from the tail vein was collected
from 90 days NDEA-treated animals.
Human blood sample collection and serum isolation
Blood samples of 24 cancer patients were collected retro-
spectively from the Tumor Tissue Repository (TTR) of
Advanced Centre of Treatment, Research and Education
in Cancer (ACTREC), Tata Memorial Centre after Ethical
Approval from Institute Ethics Committee III (Project
number 164) along with six healthy adult human volun-
teers. As the samples were collected retrospectively, insti-
tute ethics committee III approved waiver of consent for
working on patient samples. Whole blood from patients
was collected prior to surgery, allowed to clot at room
temperature for 15–30 min. The clot was then removed
by centrifugation at 5000 rpm for 10 min at 4 °C. The
resulting supernatant (serum) is transferred into multiple
tubes to avoid freeze and thaw cycles and finally stored in
liquid nitrogen containers in ACTREC, TMH-TTR. The
samples collected were from 2013 to 2016 with confirmed
histopathological tumour type as mentioned in Table 2.
Isolation of histones from serum
Total proteins were precipitated from the serum (5 ml)
by the slow addition of Trichloroacetic acid (TCA) to a
final concentration of 20% with continuous and vigorous
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mixing. The precipitation was allowed to carry out on
the ice for 30 min, followed by centrifugation at
15,000 rpm for 15 min. The obtained protein pellet was
homogenized with glass teflon homogenizer in three vol-
umes (w/v) of 0.2 M sulphuric acid (H2SO4), till the pel-
let was completely dispersed and a milky white liquid is
formed, which then was intermittently vortexed for >2 h
at 4 °C. This mixture was then centrifuged at
16,000 rpm for 20 min at 4 °C. To the supernatant ob-
tained post-centrifugation, four volumes of acetone was
added and histones were precipitated overnight at −20 °
C. The pellet obtained post-centrifugation at 16,000 rpm
for 20 min at 4 °C was washed twice with two volumes
of each of acidified acetone and acetone twice. The his-
tone pellet was air dried and eventually suspended in
50 μl of 0.1% β-mercaptoethanol in H2O and stored at
−20 °C. Histone concentrations were determined by
Bradford method of protein estimation. Protein stan-
dards were prepared containing a range of 0 to 5 μg of
bovine serum albumin in 5 ml of 1× Bradford reagent.
Histone samples were also prepared similarly. Samples
were vortexed and incubated at room temperature for
5 min. Absorbance was measured at 595 nm and the
blank was adjusted. Histone samples were estimated for
protein concentration by plotting a standard curve.
Isolation of histones from liver tissue
Histones were extracted and purified as described earlier
[18]. Briefly, liver tissues (1 g) were homogenized in
10 ml lysis buffer (15 mM Tris-Cl pH 7.5, 60 mM KCl,
15 mM NaCl, 2 mM EDTA, 0.5 mM EGTA, 0.34 M su-
crose, 0.15 mM β-mercaptoethanol, 0.15 mM spermine
and 0.5 mM spermidine) with 1× protease inhibitor
cocktail and phosphatase inhibitor cocktail. Nuclei were
then isolated by sucrose gradient centrifugation. The
three volumes of homogenate was layered on top of one
volume of 1.8 M sucrose. Nuclei pellet obtained by cen-
trifugation at 26,000 rpm for 90 min at 4 °C was resus-
pended in 0.2 M H2SO4 and incubated for >2 h at 4 °C
with intermittent vortexing. After centrifugation at
16,000 rpm for 20 min at 4 °C, the histones were precip-
itated at −20 °C for overnight with addition of four vol-
umes of acetone to the supernatant. Post-centrifugations
at 16,000 rpm for 20 mins at 4 °C, pelleted histones were
air dried and suspended in 0.1% β-mercaptoethanol in
H2O and stored at −20 °C.
Resolution and analysis of histones
The purified histones from serum and tissue that
were resolved on 18% sodium duodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) was ei-
ther stained by silver staining method [19] or transferred
to PVDF membrane, probed with site-specific modified
histone antibodies, against H4K16Ac (Millipore#07-329),
H4K20Me3 (Abcam#9053), γH2AX (Millipore#05-636),
H3S10P (Millipore#06-570), H3K27Me3 (Millipore#07-
449) and H3K9Me3 (Abcam#8898), and signals were de-
tected by ECL plus detection kit (Millipore #WBKLS0500).
Gel loading equivalence was done by silver staining
method.
Analysis of histones by LC-MS
The purified histones (15 μg) were subjected to in-solution
trypsin (20 ng/μl) digestion in 50 mM ammonium bicar-
bonate, pH 8.0 at 37 °C for 2 h (1:200 enzyme:substrate) as
described previously [20]. Enzymatic digestion was stopped
by adding 10% trifluoroacetic acid (TFA) to a final pH <3.
Peptides were then desalted with ZipTip C18 columns
(Millipore) and lyophilized prior to analysis by LTQ Orbi-
trap-MS/MS (ABSCIEX). The MS instrument was operated
in the data‐dependent mode to automatically switch be-
tween full scan MS and MS/MS acquisition. Mascot gen-
eric format (mgfs) files were generated and were searched
against protein database using Mascot version 2.3 (Matrix
Science, London, UK).
HDAC and HAT activity assays
Assays were performed using the colorimetric HDAC and
HAT activity assay kits from BioVision (BioVision Research
Products, USA) according to manufacturer’s instructions.
Briefly for HDAC activity assay, 50 μl of serum from nor-
mal, early and late tumours were diluted in 85 μl of H2O;
then, 10 μl of 10× HDAC assay buffer were added followed
by addition of 5 μl of the colorimetric substrate; samples
were then incubated at 37 °C for 1 h. Subsequently, the
reaction was stopped by adding 10 μl of lysine devel-
oper and left for additional 30 min at 37 °C. Samples
were then read in an ELISA plate reader at 405 nm.
Each sample was also treated with 2 μl (12 μM final
concentration) of Trichostatin A (TSA) for 10 min
before performing HDAC activity assay, these read-
ings are also plotted and labelled with TSA, alongside
the readings for serum samples not treated with TSA
(W/O TSA). Experiments were performed in tripli-
cates and average absorbance was plotted.
For HAT activity assay, 50 μl of serum was diluted in
80 μl H2O (final volume), and for background reading,
80 μl H2O was added in the reaction instead of the sam-
ple. Then, 50 μl of 2× HAT assay buffer was added
followed by addition of 5 μl of each of the colorimetric
substrates 1 and 2 and 8 μl NADH-generating enzyme.
The samples were incubated at 37 °C for 1 to 4 h de-
pending on the colour development. Subsequently, sam-
ples were read in an ELISA plate reader at 440 nm.
Experiments were done in triplicates and average ab-
sorbance was plotted.
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Statistical analysis
All numerical data were expressed as average of values ob-
tained ±standard deviation (SD). Statistical significance
was determined by conducting paired Student’s t test.
Results
Isolation of serum histones
We developed a minimally invasive and cost effective,
robust protocol for isolation of histones from serum
samples. This method comprises of precipitation of total
serum proteins by acid followed by purification of basic
proteins by the acid extraction method. As the method
involves precipitation and extraction by two acids, it is
referred as Dual Acid Extraction (DAE) method. There
are four key steps in the protocol: First step is the
isolation of serum from the blood; second step is the
total protein precipitation by use of trichloroacetic acid
(TCA). TCA, unlike other chemicals, precipitates all the
proteins irrespective of their molecular weight and is
also independent of the physico-chemical properties of
proteins; in the third step, histone extraction was carried
out by use of the 0.2 M H2SO4 to separate histones from
other proteins; and in the final step, acetone and acid-
ified (hydrochloric acid) acetone were used for removing
the traces of TCA or H2SO4 by replacement of sulphate
group (SO4
2−) with chloride group (Cl1−) from isolated
histones (Fig. 1). The quality of isolated histones was
checked by loading on to a 18% SDS-PAGE followed by
silver staining. The four core histones—H2A, H2B, H3
and H4—were visualized on the gel, but along with
Fig. 1 Diagrammatic representation of protocol for isolation of histones from blood. The dual acid extraction (DAE) protocol involves four crucial
steps: (1) serum isolation from blood; (2) total protein precipitation from serum by trichloroacetic acid; (3) histone extraction from precipitate by
sulphuric acid and (4) precipitation, washing and dissolution of extracted histone precipitation
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them, other high molecular weight proteins were also
noted (Fig. 2a).
To understand whether histone PTM changes ob-
served in the tissue samples can be seen in the histones
purified from the serum, we used a rat animal model
system. Hepatocellular carcinoma (HCC) was induced in
Sprague-Dawley rats by administering N-nitrosodiethyla-
mine (NDEA) in drinking water at a concentration of
1 ppm/g body weight. After 120 days of NDEA adminis-
tration, HCC was confirmed by haematoxylin and eosin
(H&E) staining (Fig. 2b). The H &E-stained slides
showed classical features of HCC like well-vascularized
tumours with wide trabeculae, prominent acinar pattern,
cytologic atypia and vascular invasion. Histones were
isolated from both the liver tissues and serum of normal
and tumour-bearing rats. The histones obtained from
serum were quantified by Bradford method using BSA
as a standard. The histone quantity in the serum of the
HCC-bearing rat group was found to be significantly
higher than the normal group (Fig. 2c (ii)). The concen-
tration was 0.8 and 5.4 μg/mL serum for normal and
tumour respectively. The purified histones from tissues
(Fig. 2c (i)) as well as serum (Fig. 2c (ii)) were resolved
on an 18% SDS-PAGE and silver stained to check their
integrity. To confirm their identity, the histones were
subjected to liquid chromatography-coupled mass spec-
trometry analysis (LC-MS). All the core histones were
identified in both the serum samples (normal and
tumour) with query coverage of >50% in case of normal
and >30% for tumour (Fig. 2d). Also, of the total 13 pro-
teins identified in serum of normal rats, three corres-
pond to histone H2A and one each to histone H3.1,
H2B and H4. In case of the serum of tumour-bearing
rats, out of the 24 proteins identified, six were of histone
H2A subtypes, two of histone H2B subtypes and one
each of H3.1 and H4 histones (Fig. 2d and Table 1).
Apart from histones, many other basic serum proteins
were also identified in MS, the details of which are pre-
sented as a part of the Table 1. Histones isolated from
the tissue were used as a positive control in LC-MS,
where all the core histones were detected with >90%
query coverage in both normal and HCC.
Fig. 2 Resolution and identification of purified histones from paired serum and liver tissue of normal and tumour. a Silver stained 18% SDS-PAGE
confirmed the integrity of the histones isolated from serum samples (1 and 2) of HCC-harboring rats by DAE protocol. All the core histones, H3,
H2A, H2B and H4 are marked with an arrow, whereas the star marks high molecular weight proteins. b H&E-stained section of normal liver and
HCC showing the altered histology in HCC at 20× and 40× magnification. c Silver-stained 18% SDS-PAGE showing the integrity of the purified his-
tones loaded in increasing volumes (5, 10 and 15 μl) (i) samples of normal and tumour tissues and (ii) serum of normal and tumour bearing rats
by the DAE protocol. The core histones H2A, H2B, H3 and H4 are marked. d Histones isolated from tissues and serum of both normal and tumour
harboring rats are subjected to LC-MS after trypsin digestion. The obtained data on number of peptides of histones identified along with se-
quence coverage are tabulated and confirmed the identity of purified proteins by DAE method. H&E haematoxylin and eosin,
NDEA N-nitrosodiethylamine
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Histone PTM pattern is comparable in liver tissues and
respective serum samples
The histone PTM profiling of normal and HCC tissues
was compared with respective serum samples by immuno-
blotting with site-specific antibodies against H4K16Ac
and H4K20Me3, as the loss of these marks are established
as hallmark of human cancer [3]. As reported for human
tumours, rat tumour tissue has also showed hypo-
acetylation and hypo-methylation at H4K16 and H4K20
respectively (Fig. 3a). Interestingly, respective serum
histones also showed the same pattern as of tissue
histones (Fig. 3a). The other crucial histone PTM marks
like γH2AX—a DNA damage mark, H3K27Me3 and
H3K9Me3—transcriptional repressive marks and H3S1
0P—a mitotic mark, known to be deregulated in many of
the human cancers [21, 22] were also probed. Intriguingly,
we noted a significant increase in these marks in both the
tumour sample tissue and serum (Fig. 3a). This shows that
the key histone modifications like acetylation, methylation
and phosphorylation are retained during the course of his-
tone extraction from serum samples by DAE method and
also profiling between tissue samples and their respective
serum samples mirrored each other.
In order to understand that the changes seen in serum
histone is due to liver tumour and not due to changes in
the entire PTM profile of all the other organs, we
profiled for histone PTMs in the lung, kidney and brain
isolated from both the normal and NDEA-treated
(tumour-bearing) animals. The tissues isolated from the
animals treated with NDEA were first histologically
examined for any aberrations by H&E staining (Fig. 3b).
Grossly, no differences were seen with respect to control
tissues in untreated animals. Histones were then isolated
and probed for site-specific PTM antibodies (Fig. 3c).
The data demonstrates that the alterations of modifications
are specific to tumour liver tissue and not to other histolog-
ically normal organs, thus strengthening that the liquid
biopsy (serum histone) is very similar to its parent tissue
(tumour tissue-liver) and hence can be used for clinical
purpose.
Increased HDAC activity in HCC tissues correlates with
corresponding serum samples
So far, we have seen a positive correlation for histone
PTMs in HCC, tissue and serum histones. We next con-
templated whether the reported increased HDAC activ-
ity in tumour tissue [23] can also be seen in serum to
understand how similar the liquid biopsy (serum) is to
tissue biopsy in context of histone PTM modifiers. This
is particularly interesting due to the observation of H4
hypo-acetylation seen in serum and HCC purified his-
tones. HDAC activity assay conducted using serum iso-
lated from normal, early (90 days NDEA treatment) and
late stage (120 days NDEA treatment) HCC-bearing rats
demonstrated the presence of significantly higher HDAC
activity in both the tumour serum samples and normal
serum (Fig. 3d (i)). Interestingly, the serum of early stage
liver cancer animals also showed an elevated HDAC in
comparison to normal, indicating that HDAC activity
gradually increases during the course of HCC develop-
ment (Fig. 3d (i)). As a proof of principle that the calori-
metric assay performed is indeed a true measure of
Table 1 Total proteins detected in LC-MS of serum and tissue purified histories of normal and tumour samples
Proteins Tissue normal Tissue tumour Serum normal Serum tumour
Histones H2A type 1 (91.5%)
H2A type 2-A (91.5%)
H2A type 1-C (91.5%)
H2A type 1-F (86.1%)
H2B type 1E (91.5%)
H2B type 1C (91.5%)
H3.1 (99.2%)
H4 (59.2%)
H2A type 2-A (98.4%)
H2A type 1-C (98.4%)
H2B type 1E (98%)
H3.1 (99.2%)
H4 (98.4%)
H2A type 2-A (81.5%)
H2A type 1 (74.62%)
H2A type 1-C (50%)
H3.1 (59.2%)
H2B type 1E (57%)
H4 (60%)
H2A type 2-A (46.9%)
H2A type 1-C (33%)
H2A type 1-F (38.4%)
H2A type 1-E (30%)
H2A type 1 (33%)
H2A type 4 (33%)
H2B type 1E (57%)


















Fibrinogen beta chain (65.75%)
Fibrinogen alpha chain (56.91%)
Isoform 2 of Fibrinogen alpha
(69.45%)
Isoform 2 of Fibrinogen beta
chain (70.96%)





Fibrinogen beta chain (65.3%)
Fibrinogen alpha chain (43.3%)
Isoform 2 of Fibrinogen beta chain (67.4%)
Isoform 2 of Fibrinogen alpha chain (59.6%)
Matrix estracellular phosphoglycoprotein (60%)




Indoleamine 2.3-dioxygenase 1 (37.8%)
Aldehyde oxidase 2 (29.6%)
Astrocytic phosphoprotein (69.9%)
Transcription factor YY2 (32.9%)
Cannabinoid receptor 1 (11.1%)
Putative pheromone receptor (19.1%)
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HDAC activity, treatment of serum samples with TSA was
done prior to HDAC assay. As seen in (Fig. 3d (i)), the ac-
tivity in samples treated with TSA is less compared to the
untreated samples validating the robustness of the assay.
To understand the status of HATs, levels of which are also
reported to change in human tumours [24], we performed
a HAT activity assay in normal, early and late stages of
tumour serum, but no significant differences were ob-
served, suggesting the H4 hypo-acetylation seen might be
due to enhanced HDAC activity in tumour samples com-
pared to normal (Fig. 3d (ii)).
Intrigued by the observation of elevated HDAC activ-
ity in tumour serum samples of rat model, we asked
whether the HDAC activity can also be detected in hu-
man serum samples. To this end, we performed HDAC
activity assay in serum isolated from six healthy subjects
(normal) and 24 different types of cancer patients, in-
cluding colorectal (CRC#6), buccal (BM#7), tongue
(TNG#6), breast (BC#2) and glioblastoma (GBM#2).
The histopathological details of patient samples included
in the study are tabulated in Table 2. The cumulative
analysis of all the 24 samples revealed a higher HDAC
Fig. 3 Profiling of site-specific histone modifications and modifiers in paired serum and liver tissue of normal and tumour. a (i) Western blots of
histones isolated from tissues and serum with site-specific histone PTM antibodies of H4K20Me3, H3K27Me3, H3K9Me3, γ-H2AX, H3S10P and H4K16Ac in
tumour tissue and serum compared to normal. Antibodies against H3 and H4, and fast green-stained histone transferred PVDF membrane were used as
equal loading control. b H&E-stained section (×40) of tissues (lung, kidney and brain) from NDEA-treated or untreated (normal) animals. c Western
blotting of histones isolated from normal tissues (lung, kidney and brain) and serum of NDEA-treated or untreated animals with site-specific histone
PTM antibodies against H4K20Me3, γ-H2AX, H3S10P and H4K16Ac. Antibodies against H3 and H4, and fast green-stained histone transferred PVDF
membrane were used as equal loading control. d Colorimetry-based assay done using serum isolated from normal, early and late stage
tumour bearing rats (i) HDAC activity assay was performed on both the TSA-treated and untreated samples (ii) HAT activity. Statistical
tests are done by using Student’s t test. *p < 0.05, **p < 0.01
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activity in serum of cancer patients compared to normal
(Fig. 4a) with no significant change in HAT activity
(Fig. 4b). Also, grouping of serum samples based on the
cancer type shows an elevated activity in most of the
samples of CRC (Fig. 4c), buccal (Fig. 4d), tongue
(Fig. 4e), and breast and glioblsatoma (Fig. 4f ).
Interestingly, we found that even with a sample size of
24, the HDAC activity is different amongst each patient
sample, therefore, highlighting the importance of sub-
grouping the patients on the basis of inherent epigenetic
background for success of epigenetic drugs (epi-drug)
therapy. Thus, monitoring the HDAC activity in the
serum sample has helped us to categorize the patients
into two subgroups: (1) high HDAC and (2) low HDAC
(Fig. 4g). Group 1 can further be subdivided into two,
high and moderate HDAC activity groups (Fig. 4g). This
subgrouping of patients on the basis of HDAC activity
will assist in selection of patients, determining the dose
of epi-drug, thus increasing the success of therapy.
During the diagnosis of a disease like cancer, measure-
ment of many serum based biomarkers is usually
performed. One such marker is the quantification of serum
CEA levels in CRC patients. We observed differential levels
of CEA amongst the six CRC samples used in the study.
Interestingly, high CEA levels seen for CRC02 and CRC05
samples correlated with high HDAC activity in comparison
to other samples with low CEA values (Fig. 4h). Thus,
serum based measurement of HDAC activity compares
positively to CEA, a cancer biomarker for CRC.
Discussion
The DAE protocol developed for the isolation of his-
tones from serum samples is simple, robust, time effi-
cient and cost effective. Further, the comparison of key
site-specific histone PTMs in tissue versus serum, for
both normal and tumour samples, has revealed a similar
pattern amongst the respective biological samples. Also,
we illustrate for the first time a higher HDAC activity in
serum tumour sample compared to normal.
Earlier protocols for isolation of cNUCs are based on
chromatin immunoprecipitation (ChIP) by specific his-
tone antibodies. ChIP depends critically on the quality of
the antibody and is not cost-effective. Though numerous
histone antibodies as ChIP-grade are available, they need
stringent validation by western blotting and MS, because
of their cross-reactivity with unmodified histones, simi-
lar histone modifications and some with non-histone
proteins. The developed protocol overcomes all the limi-
tations of the existing ChIP method as it is based on dual
acid extraction. The good quality and quantity of purified
histones by this novel technique has opened a new avenue
for studying the pattern of histone PTMs as well as his-
tone variants in serum samples by western blotting or
mass spectrometry in different pathophysiological states.
To gain insights into global serum histone PTM pat-
tern and understand whether the observed alteration
matches with that of the cancer tissue, NDEA-induced
HCC rat model system has been used. The quantity of
histones isolated from the normal serum was very less
compared to the serum samples of NDEA-induced HCC
rats (Fig. 2c (ii)). This could be directly attributed to the
increased cell death seen in diseased conditions as
opposed to the healthy subjects, due to which the abun-
dance of cNUCs and hence histones will be more in a
serum sample of diseased state. This is in conformity
with the earlier reports where elevated cNUCs are ob-
served in various human cancers [6, 10, 12, 25].
Studies on global histone modifications across various
human cancers have identified alterations in a panel of
histone PTMs [26]. The loss of H4K16Ac and H4K20Me3
are now regarded as the hallmark of most human cancers
[3]. Interestingly, we noted that these hallmarks are even
true for the animal model system. Furthermore, similar
changes are observed in serum histones also proving that
indeed they are true hallmarks which change during
Table 2 Histopathological analysis of human patient samples
used in the study
Sample Origin Histopathological analysis
BM01 Buccal Moderately differentiated squamous carcinoma
BM02 Buccal Moderately differentiated squamous carcinoma
BM03 Buccal Moderately differentiated squamous carcinoma
BM04 Buccal Moderately differentiated squamous carcinoma
BM05 Buccal Moderately differentiated keratinizing squamous
carcinoma
BM06 Buccal Moderately differentiated keratinizing squamous
carcinoma
BM07 Buccal Poorly differentiated squamous carcinoma
TNG01 Tongue Moderately differentiated squamous carcinoma
TNG02 Tongue Moderately differentiated squamous carcinoma
TNG03 Tongue Moderately differentiated squamous carcinoma
TNG04 Tongue Squamous carcinoma
TNG05 Tongue Moderately differentiated squamous carcinoma
TNG06 Tongue Moderately differentiated squamous carcinoma
CRC01 Colon Moderately adenocarcinoma
CRC02 Colon Poorly differentiated adenocarcinoma
CRC03 Colon Moderately differentiated adenocarcinoma
CRC04 Colon Moderately differentiated adenocarcinoma
CRC05 Rectum Moderately differentiated adenocarcinoma
CRC06 Rectum Adenocarcinoma
BC01 Breast Infitrating duct carcinoma, Grade II
BC02 Breast Infitrating lobular carcinoma, Grade II
GBM01 Glioblastoma Glioblastoma (WHO grade IV)
GBM02 Glioblastoma Glioblastoma (WHO grade IV)
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cancer, irrespective of the cancer type in the study, species
used and source of biological samples (liquid or solid bi-
opsy). Profiling for other histone PTMs—H3K27Me3,
H3K9Me3, γH2AX and H3S10P, in both tissue and serum
showed a same pattern of increase in tumour tissue and
serum samples. Further, we also reveal that the changes in
the histone PTM pattern observed in serum mirrors only
liver tissue and no other organs, thus proving that the his-
tones in serum are from tumour tissue.
Earlier studies had shown the presence of acetylated his-
tones in blood cells, but its levels were not correlated with
tumour tissue [27]. Such studies on global histone modifi-
cations are of importance because of their prognostic util-
ity and predictive markers for recurrence. Now with the
serum histones showing a similar pattern of histone PTMs
as of tumour tissue, liquid biopsy (non-invasive) will be a
good alternative to tissue biopsy (invasive) for monitoring
the disease regression/progression in cancer patients.
Further, the antitumour effects of histone deacetylase or
histone methyltransferase inhibitors could be evaluated by
monitoring changes in the quantities of the corresponding
modification on the circulating histones thus overcoming
the limitation of earlier studies wherein histones of blood
cells were used.
Altered histone acetylation levels in cancer are the re-
sult of the imbalance of the activities of HAT and
HDAC. Many reports have emphasized the altered levels
of these enzymes, especially HDACs in various cancers
[28]. Our data of an increased HDAC activity in serum
and tumour tissue samples compared to normal is in ac-
cordance with the earlier reports. Thus, the present ob-
servation of HDAC activity in serum allows us to
monitor the level of HDAC and possible tumour status
in response to histone-modifying enzyme inhibitors in
real time by liquid biopsy. Interestingly, some studies on
global proteomic profiling of serum proteins has earlier
Fig. 4 Profiling of histone modifiers in human serum samples. Cumulative analysis of a HDAC and b HAT activity assays done using the human
serum of six healthy subjects and 24 cancer patients. With TSA—involves serum pre-treated with TSA for 10 min and without TSA—untreated
samples. Graph showing the relative activity of HDACs in c CRC, d buccal, e tongue, f breast and glioblastoma samples. Statistical tests are done
by using Student’s t test. *p < 0.05, **p < 0.01. g Table representing the subgrouping of all 24 human samples as per their HDAC activities. h
Correlation between serum CEA levels and HDAC activity in six CRC samples. Highlighted samples show high CEA and HDAC levels
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reported the presence of HDACs in serum, thus it is
not surprising that HDAC activity is detected in serum
[29, 30]. Intriguingly, measurement of HDAC activity in
early (90 days NDEA treatment) and late (120 days NDEA
treatment) stages of liver cancer in an animal model sys-
tem revealed a gradual increase in HDAC activity as the
animal develops a tumour. This observation proves that
early monitoring of HDAC activity may assist in better
diagnosis of cancer. Further, the assay can be employed to
monitor the naive cancer, recurring and drug resistant tu-
mours, where in periodic monitoring of HDAC activity in
patients diagnosed with cancer will aid in their improved
clinical management. However, large studies including
more cancer patients at various stages, undergoing diverse
chemotherapeutic treatments in combination with epi-
drugs will provide conclusive evidences and help in
employing the proposed hypothesis for better disease
management.
Owing to the increased HDACs, use of HDAC inhibi-
tors for treatment of cancer is considered to be a good
treatment regime. But so far, the use of HDAC inhibitors
had limited success in solid tumours because of severe
toxicities and other fatal effects [31]. One of the reasons
behind the failure or limited success of HDAC inhibitors
has been attributed to the inherent epigenetic back-
ground of the patients, where some may have high ex-
pression of HDACs others low levels [32, 33]. This can
further be seen in our data, where all the patients
showed different extent of HDAC levels (Fig. 4c, f ).
Therefore, administering HDAC inhibitors to patients
with inherent low levels of HDACs may be fatal. For ex-
ample, based on our data, we have segregated the sam-
ples into two groups, HDAC high and HDAC low
(Fig. 4g). Treating the first group patients with HDAC
inhibitors will be beneficial, as this group show elevated
levels of these enzymes. Furthermore, this group can be
subdivided into two, which can help in deciding the dose
and time span of epi-drug therapy, where a high HDAC
activity patient can be given high doses of drugs for a
longer span than the others. As for the second group,
epi-drug treatment might not be of much benefit. Thus,
serum-based detection of histone modifiers like HDAC/
HAT will help with subgrouping of patients and
personalize the treatment, monitor patient’s health status
during treatment with histone modifier inhibitors and
response of the individual’s tumour to treatment (Fig. 5).
Conclusions
In summary, the developed DAE technique for isolating
serum histones will provide real time information of epi-
genome which will be helpful in understanding the over-
lap between paired serum and cancer tissue histone
proteome by high-end proteomics. Importantly, our data
gave a novel rationale for using serum histone proteomics
as a predictive tool for disease progression. This informa-
tion will allow the development of efficient strategies for
the treatment and better management of the underlying
disease. The combination of different histone marks rather
than a single histone mark is believed to further enhance
sensitivity and specificity of detection of these marks and
hence improve cancer management.
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